Merck, Inc.
🇺🇸United States
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
Phase 2
Completed
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 240
- Registration Number
- NCT01697579
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 751
- Registration Number
- NCT01682759
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
Phase 3
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Sitagliptin/Simvastatin FDCDrug: Placebo to Sitagliptin/Simvastatin FDC
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 299
- Registration Number
- NCT01678820
Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)
Phase 1
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- Procedure: Liver samples from FNABiological: Peg-IFN alfa-2bProcedure: Liver samples from CNBBiological: Ribavirin
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 31
- Registration Number
- NCT01678131
Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2438
- Registration Number
- NCT01667081
A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26
- Registration Number
- NCT01667107
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
Phase 4
Completed
- Conditions
- Ankylosing Spondylitis
- Interventions
- Biological: Golimumab
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 101
- Registration Number
- NCT01668004
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)
Phase 1
Completed
- Conditions
- HypertensionIsolated Systolic Hypertension
- Interventions
- Drug: Placebo for MK-8150
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 103
- Registration Number
- NCT01656408
A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012)
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 576
- Registration Number
- NCT01656395
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 56
- Registration Number
- NCT01651936